
Cannabis at an Inflexion Point: Why Capital Is Missing the Opportunity
For much of the past five years, the cannabis industry has been defined by disappointment. Public equities are down approximately

For much of the past five years, the cannabis industry has been defined by disappointment. Public equities are down approximately

Jersey’s medical cannabis industry turned a profit for the first time in 2025, posting revenues of £12m, almost £50m in

Ananda Pharma, now the leading force in pharmaceutical cannabis research in the UK, has announced that the former Chief Operating

A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.

British American Tobacco [stock_market_widget type=”chart” template=”line” assets=”BATS.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Tobacco giant

UK-based biotech firm Ananda Developments has solidified its position as a driving force in clinical cannabis research in Europe, announcing the launch of two more major trials using its proprietary compounds.

As reported by Cannabis Health Avata Biosciences is developing solid dose cannabinoid medicines for epilepsy and other neurological disorders, with

Germany’s passage of CanG continues to drive up stock prices Yesterday, the President of Bundesrat, Manuela Schwesig, signed Germany’s landmark

Big pharma has so far been cautious of diving headfirst into the cannabis industry, despite the growing body of evidence

German Stocks Spike on Passage of Draft Law [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”SBX.DE” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”]

WITH the fast-growing CBD sector tied up in a regulatory quagmire hundreds of transatlantic industry players face an uncertain future. However, one